Stay updated with breaking news from Broadview Ventures. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Cardiosense, a digital health company developing a non-invasive monitoring platform for the early detection of heart disease, recently started...
This 'should help eradicate the current somewhat nihilistic approach' to managing atrial fibrillation in advanced heart failure, said an expert.
/PRNewswire/ -- Acesion Pharma ("Acesion" or "the Company"), a biotech company pioneering first-in-class novel therapies for atrial fibrillation ("AF"), the...
/PRNewswire/ -- Acesion Pharma ("Acesion"), the biotech pioneering first-in-class novel therapies for Atrial Fibrillation ("AF"), the most common cardiac...
-BB-031, a potential rapid onset, short-acting and reversible thrombolytic, targets von Willebrand Factor, a key structural component of thrombi and driver of blood clotting--Company to initiate a Phase 2 clinical proof-of-concept study of BB-031 in patients with acute ischemic stroke-COLUMBUS, Ohio--(BUSINESS WIRE)...